Smart Medical Devices Market: as GE HealthCare tops the FDA's AI-enabled medical device authorisation list for a fourth consecutive year with 100 total clearances while Philips secures clearance for dual-AI MRI software scalable across its entire installed base, the two largest imaging companies are demonstrating fundamentally different paths to AI-enabled device scale, one building a broad authorisation portfolio spanning modalities, the other extracting maximum value from AI capability deployed across an already-massive existing hardware fleet.

The global smart medical devices market size was USD 142.84 Billion in 2025 and is expected to register a revenue CAGR of 8.1% during the forecast period. Market revenue growth is driven by factors such as AI-enabled diagnostic imaging capability reaching scaled commercial deployment across major manufacturer installed bases, IoT sensor integration and continuous remote patient monitoring connectivity extending device intelligence beyond the point of care, and expanding regulatory clearance volume for AI and machine learning-enabled medical devices establishing a mature approval pathway. The first driving factor is AI-enabled diagnostic imaging capability reaching scaled commercial deployment, as manufacturers extend AI algorithms from individual device clearances into fleet-wide deployment across their existing installed hardware base. AI-enabled diagnostic imaging systems account for a substantial share of total 2025 market revenue, reflecting this category's centrality to the smart medical device market's most commercially mature application. The second driving factor is IoT sensor integration and continuous remote patient monitoring connectivity, which extends device intelligence beyond the point of care into ongoing patient physiological surveillance. The third driving factor is expanding regulatory clearance volume for AI and machine learning-enabled medical devices, as the FDA's approval pathway for this device category matures and clearance volume scales substantially year over year. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single AI algorithm's deployment across a manufacturer's entire existing installed hardware fleet converts what would otherwise require a new hardware purchase decision at each hospital account into a software-deployable capability upgrade, which lets the manufacturer capture AI-enabled revenue from its full existing customer base simultaneously rather than waiting for each account's next hardware replacement cycle. Because a hospital's existing imaging hardware represents a substantial, multi-year capital investment that hospitals do not replace simply to access new AI capability, a manufacturer that can deploy AI algorithms as a software upgrade across its already-installed hardware fleet captures revenue from its full existing customer base far faster than waiting for the natural hardware replacement cycle would allow. As a result, demand and revenue share are concentrating around manufacturers with both the largest installed hardware base and the software architecture to deploy AI capability across that base efficiently, and the forecast reflects this fleet-wide deployment model as a distinct driver of the market's fastest-scaling revenue segment. For instance, in July 2025, Philips received FDA 510(k) clearance for SmartSpeed Precise dual AI software, now cleared for clinical use across Philips' entire portfolio of 1.5T and 3.0T MRI systems including its extensive existing installed base, making it one of the most scalable innovations in the MRI market by design. These are some of the key factors driving revenue growth of the market.

Because the EU Artificial Intelligence Act establishes a risk-based regulatory framework for high-risk AI applications including AI-enabled medical devices that manufacturers must satisfy in addition to existing EU MDR requirements, this dual compliance burden adds genuine regulatory complexity and cost specifically for manufacturers seeking to market AI-enabled smart devices in the European market.

Cybersecurity vulnerability management requirements adding ongoing compliance cost are a second constraint, since FDA premarket cybersecurity guidance requires software bill of materials documentation, coordinated vulnerability disclosure processes, and post-market cybersecurity patch capability for all network-connected device submissions, creating an ongoing compliance obligation that persists well beyond initial device clearance.

AI algorithm performance drift and post-market monitoring uncertainty is a third constraint, since an AI algorithm's real-world performance can shift over time as patient populations and clinical practice patterns evolve, and the regulatory and clinical framework for ongoing AI algorithm performance monitoring after initial clearance remains an area of continued development rather than full maturity.

These factors substantially limit smart medical devices market growth over the forecast period.

The clearest driver of demand is AI-enabled diagnostic imaging capability reaching scaled commercial deployment, as manufacturers extend AI algorithms from individual device clearances into fleet-wide deployment across their existing installed hardware base. A radiology department facing rising imaging volume and workforce shortage pressure benefits directly from AI capability that improves scan speed and diagnostic confidence without requiring new hardware, so software-deployable AI algorithms that work across an already-installed system represent a uniquely efficient path to capability improvement for hospitals operating under real capital budget constraints. AI-enabled diagnostic imaging systems account for a substantial share of total 2025 market revenue, and GE HealthCare topped the FDA's list of AI-enabled medical device authorisations for the fourth consecutive year in July 2025, reaching 100 total listed authorisations reflecting sustained investment across imaging modalities. The effect on the market is that AI-enabled imaging capability is becoming a genuine competitive differentiator measured by the breadth and pace of a manufacturer's clearance portfolio, not just individual flagship product capability. These are some of the key factors driving revenue growth of the market.

The second driver is IoT sensor integration and continuous remote patient monitoring connectivity, which extends device intelligence beyond the point of care into ongoing patient physiological surveillance across care settings. A conventional medical device provides data only at the moment of use, while a connected smart device continuously captures and transmits physiological data that clinicians can monitor between formal care encounters, so this connectivity directly addresses the visibility gap between scheduled clinical visits that has historically limited early detection of patient deterioration or condition change. Philips received FDA clearance for its IntelliVue Patient Monitor MX750 with an AI early warning algorithm performing 17-parameter continuous physiological analysis, generating a patient deterioration risk score up to four hours before conventional clinical signs would indicate the same risk. The effect on the market is that continuous connected monitoring is becoming a standard expectation for patient monitoring device capability, not simply a premium feature differentiating select platforms. These are some of the key factors driving revenue growth of the market.

Philips' SmartSpeed Precise dual AI MRI software, FDA-cleared in July 2025, is scalable across the company's entire existing 1.5T and 3.0T installed base by design. GE HealthCare's fourth consecutive year atop the FDA's AI authorisation list, reaching 100 total clearances, reflects a parallel but structurally different path to the same fleet-wide AI deployment scale.

The third driver is expanding regulatory clearance volume for AI and machine learning-enabled medical devices, as the FDA's approval pathway for this device category matures and clearance volume scales substantially year over year. A maturing, well-established regulatory pathway reduces the uncertainty manufacturers face when planning AI-enabled device development investment, so sustained growth in annual clearance volume signals both regulatory pathway maturity and continued manufacturer confidence in pursuing AI-enabled device development at scale. The FDA's Digital Health Center of Excellence documented more than 950 AI and machine learning-enabled device submissions in a single year, the largest annual AI medical device clearance volume on record, with radiology, cardiology, and ophthalmology leading by application area. The effect on the market is that the breadth of clinical specialties pursuing AI-enabled device development continues expanding beyond the historically dominant radiology application into a genuinely broader range of clinical domains. These are some of the key factors driving revenue growth of the market.

However, the smart medical devices market faces severe adoption constraints from dual compliance burden under the EU Artificial Intelligence Act and EU MDR for AI-enabled medical device manufacturers, and cybersecurity vulnerability management requirements adding ongoing compliance cost for network-connected device manufacturers.

Because the EU Artificial Intelligence Act establishes a risk-based regulatory framework for high-risk AI applications including AI-enabled medical devices that manufacturers must satisfy in addition to existing EU MDR requirements, this dual compliance burden adds genuine regulatory complexity and cost specifically for manufacturers seeking to market AI-enabled smart devices like Philips' SmartSpeed Precise in the European market.

Cybersecurity vulnerability management requirements adding ongoing compliance cost compound this, since FDA premarket cybersecurity guidance requires software bill of materials documentation, coordinated vulnerability disclosure processes, and post-market cybersecurity patch capability for all network-connected device submissions, creating an ongoing compliance obligation that persists well beyond initial device clearance.

AI algorithm performance drift and post-market monitoring uncertainty is the third constraint, since an AI algorithm's real-world performance can shift over time as patient populations and clinical practice patterns evolve, and the regulatory and clinical framework for ongoing AI algorithm performance monitoring after initial clearance remains an area of continued development rather than full maturity.

These factors substantially limit smart medical devices market growth over the forecast period.

Based on device type, the global smart medical devices market is segmented into smart wearable monitors, smart implantable devices, AI-enabled diagnostic imaging systems, connected point-of-care devices, smart infusion and drug delivery systems, and connected patient monitoring platforms. AI-enabled diagnostic imaging systems hold the largest revenue share, because GE HealthCare's and Philips' fleet-wide AI deployment models represent the smart medical device market's most commercially mature and scaled application, which suits a market where the most established smart device category commands the largest revenue category. Connected patient monitoring platforms remain a substantial, closely established second category anchored by platforms like Philips' IntelliVue MX750. Smart implantable devices are expected to register a significant revenue growth rate in the global smart medical devices market over the forecast period, driven by expanding sensor-embedded implant technology across orthopedic and cardiac categories.

Radiology and diagnostic imaging application is expected to account for the largest revenue share in the global smart medical devices market during the forecast period

Based on application, the global smart medical devices market is segmented into cardiology and cardiac monitoring, diabetes and metabolic management, radiology and diagnostic imaging, critical care and patient deterioration detection, respiratory monitoring, and neurological monitoring. Radiology and diagnostic imaging holds the largest revenue share, reflecting the FDA's documented leadership of this application area in AI and machine learning-enabled device clearance volume. Critical care and patient deterioration detection is expected to register the fastest revenue growth rate in the global smart medical devices market over the forecast period, driven by Philips' IntelliVue MX750 AI early warning algorithm and comparable predictive deterioration detection platforms.

Hospitals and clinical facilities end-use is expected to account for the largest revenue share in the global smart medical devices market during the forecast period

Based on end-use, the global smart medical devices market is segmented into hospitals and clinical facilities, home care and remote patient monitoring, and ambulatory and outpatient facilities. Hospitals and clinical facilities hold the largest revenue share, reflecting the concentration of AI-enabled imaging and critical care monitoring device deployment within hospital-based clinical settings. Home care and remote patient monitoring is expected to register the fastest revenue growth rate in the global smart medical devices market over the forecast period, driven by continued IoT sensor and connectivity integration extending device intelligence beyond hospital settings.

Based on regional analysis, the smart medical devices market in North America accounted for largest revenue share in 2025. The United States leads because the concentration of FDA AI/ML device clearance activity and the world's largest annual clearance volume create the deepest smart medical device demand globally, and because GE HealthCare, Abbott, and Medtronic all maintain their primary commercial presence in the US market. GE HealthCare's fourth consecutive year topping the FDA's AI authorisation list specifically reinforces the depth of US-anchored AI medical device innovation. The concentration of FDA Digital Health Center of Excellence activity in the country also means new AI-enabled device categories are typically established in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the Netherlands, and France represent the three largest national markets within Europe, anchored by Philips' Dutch headquarters and Siemens Healthineers' German operations. The EU Artificial Intelligence Act's dual compliance requirement with EU MDR specifically shapes ongoing manufacturer compliance investment across the region. The result is steady rather than rapid growth, shaped more by dual regulatory compliance cost than by underlying demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China and Japan represent two of the largest national markets within the region, driven by expanding hospital AI adoption and rising connected device infrastructure investment. The region's rapidly scaling healthcare digitisation leaves considerably more room for growth than in the already smart-device-mature North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national markets within the region, with expanding hospital AI and connected device adoption driving early smart medical device demand growth. The ongoing Iran-US sanctions and the resulting Strait of Hormuz shipping disruption have raised freight and import costs for the specialised semiconductors and sensor components that Latin American smart device distributors depend on, an effect expected to run through 2026 and slow smart medical devices adoption beyond Brazil's and Mexico's main urban centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial markets within the region. Saudi Arabia's expanding hospital digitisation investment and the UAE's regional distribution hubs represent the primary investment centres for smart medical devices adoption. Saudi Arabia is the most established market on the continent, while the Gulf states outside it are still building the connected healthcare infrastructure needed to support advanced smart device platforms at scale.